Chiome Bioscience Management

Management criteria checks 2/4

Chiome Bioscience's CEO is Shigeru Kobayashi, appointed in Feb 2017, has a tenure of 7.25 years. directly owns 0.44% of the company’s shares, worth ¥29.54M. The average tenure of the management team and the board of directors is 7.1 years and 3.2 years respectively.

Key information

Shigeru Kobayashi

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7.3yrs
CEO ownership	0.4%
Management average tenure	7.1yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO

Shigeru Kobayashi (70 yo)

7.3yrs

Tenure

Mr. Shigeru Kobayashi, M.E., has been Chief Executive Officer and President at Chiome Bioscience Inc. since February 18, 2017. Mr. Kobayashi has been an Executive Director of Business Planning and Developm...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shigeru Kobayashi	CEO, President & Executive Director	7.3yrs	no data	0.44% ¥ 29.5m
Arihiko Bijohira	CFO, Head of Corporate Planning Officer & Executive Director	7.1yrs	no data	0.078% ¥ 5.2m
Ryuji Osawa	Head of Business Development and Executive Officer	8.3yrs	no data	no data
Teruyo Taoka	GM of Development Division & Director	3.9yrs	no data	0.041% ¥ 2.8m
Masamichi Koike	Head of Research Division & Executive Director	1.3yrs	no data	0.023% ¥ 1.6m

7.1yrs

Average Tenure

57.5yo

Average Age

Experienced Management: 4583's management team is seasoned and experienced (7.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shigeru Kobayashi	CEO, President & Executive Director	no data	no data	0.44% ¥ 29.5m
Arihiko Bijohira	CFO, Head of Corporate Planning Officer & Executive Director	7.1yrs	no data	0.078% ¥ 5.2m
Teruyo Taoka	GM of Development Division & Director	1.2yrs	no data	0.041% ¥ 2.8m
Masamichi Koike	Head of Research Division & Executive Director	1.2yrs	no data	0.023% ¥ 1.6m
Yoshiyuki Yamakawa	Audit & Supervisory Board Member	4.2yrs	no data	no data
Akiyuki Furuya	Audit & Supervisory Board Member	no data	no data	0.023% ¥ 1.6m
Haruhisa Kubota	Independent Outside Director	no data	no data	no data
Niro Sakamoto	Audit & Supervisory Board Member	3.2yrs	no data	no data

3.2yrs

Average Tenure

62yo

Average Age

Experienced Board: 4583's board of directors are considered experienced (3.2 years average tenure).

Chiome Bioscience Management

Management criteria checks 2/4

Key information

Recent management updates

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2024

Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2023

No independent directors

No independent directors

Chiome Bioscience Inc., Annual General Meeting, Mar 25, 2022

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2021

Recent updates

Chiome Bioscience Inc. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released: JP¥24.13 loss per share (vs JP¥28.26 loss in FY 2022)

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2024

Chiome Bioscience Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: JP¥5.25 loss per share (vs JP¥5.79 loss in 3Q 2022)

Chiome Bioscience Inc. to Report Q3, 2023 Results on Nov 14, 2023

Chiome Bioscience Inc. announced that it expects to receive ¥13.49304 million in funding

Chiome Bioscience Inc. to Report Q2, 2023 Results on Aug 09, 2023

Full year 2022 earnings released: JP¥28.26 loss per share (vs JP¥36.74 loss in FY 2021)

Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2023

Chiome Bioscience Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: JP¥5.96 loss per share (vs JP¥10.77 loss in 3Q 2021)

No independent directors

Chiome Bioscience Inc. to Report Q3, 2022 Results on Nov 14, 2022

First half 2022 earnings released: JP¥18.17 loss per share (vs JP¥10.16 loss in 1H 2021)

Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial

Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study

Chiome Bioscience Inc. to Report Q2, 2022 Results on Aug 10, 2022

No independent directors

Chiome Bioscience Inc. to Report Q1, 2022 Results on May 13, 2022

Chiome Bioscience Inc. Submits an Initial Application for Phase I Study on CBA-1535

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chiome Bioscience Inc., Annual General Meeting, Mar 25, 2022

Chiome Bioscience Inc. Announces Move to the Second Half Part of Phase 1 Clinical Trial of First-In-Class CBA-1205

Chiome Bioscience Inc. announced that it has received ¥16.8 million in funding from SMBC Nikko Securities Inc., Investment Arm

Chiome Bioscience Inc. announced that it expects to receive ¥16.8 million in funding from SMBC Nikko Securities Inc., Investment Arm

Second quarter 2021 earnings released: JP¥6.16 loss per share (vs JP¥9.25 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥4.07 loss per share (vs JP¥12.78 loss in 1Q 2020)

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2021

Chiome Bioscience Inc. to Report Fiscal Year 2020 Results on Feb 09, 2021

Shanghai Henlius Biotech, Inc. Enters into Exclusive License Agreement with Chiome Bioscience Inc. for Development and Commercialization of the Anti-Tpor-2 Antibodies, Liv-2008/2008B

New 90-day high: JP¥241

New 90-day low: JP¥203

Chiome Bioscience Inc. Announces Amendment to the License Agreement with ADC Therapeutics

Chiome Bioscience Inc. to Report Q3, 2020 Results on Nov 10, 2020

Chiome Bioscience Inc. to Report Q2, 2020 Results on Aug 11, 2020

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age